Sirolimus-based immunosuppression improves outcomes in liver transplantation recipients with hepatocellular carcinoma beyond the Hangzhou criteria

BACKGROUND: The administration of calcineurin inhibitors (CNIs) posttransplant has been implicated as an independent risk factor for the recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT). The new immunosuppressive agent sirolimus (SRL) acts as a primary immunosuppressant...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ann Transl Med
Hauptverfasser: Ling, Sunbin, Feng, Tingting, Zhan, Qifan, Duan, Xin, Jiang, Guangjiang, Shen, Tian, Shan, Qiaonan, Xu, Shengjun, Ye, Qianwei, Liu, Peng, Cen, Beini, Zheng, Shusen, Xu, Xiao
Format: Artigo
Sprache:Inglês
Veröffentlicht: AME Publishing Company 2020
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7049005/
https://ncbi.nlm.nih.gov/pubmed/32175373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2020.01.10
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge